Physician profile
Stephen Bell
NPI 1215425749
$3,587.74
in general payments reported to CMS, 2019-2025
16 companies · $760 in 2025
The $760 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.48 · 2021: $13.89 · 2022: $152 · 2023: $712 · 2024: $1,927 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,244 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,244.29 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $782.71 | 2022-2025 | Enbrel, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $496.27 | 2024-2025 | |
| Pfizer INC. | $370.74 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $347.10 | 2023-2024 | Saphnelo |
| Janssen Biotech, INC. | $299.56 | 2023-2024 | Tremfya, Simponi Aria |
| Ucb, INC. | $244.86 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $242.42 | 2024-2025 | Orencia |
| Abbvie INC. | $198.61 | 2020-2025 | |
| Genzyme Corporation | $192.08 | 2023-2024 | |
| Glaxosmithkline, LLC. | $101.97 | 2023-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $96.27 | 2023 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $94.99 | 2023 | |
| Lilly USA, LLC | $49.42 | 2023-2024 | Taltz |
| Alexion Pharmaceuticals, INC. | $33.50 | 2025 | Strensiq |
| Radius Health, INC. | $23.35 | 2024 | Tymlos |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.